20 Mg Furosemide And 3 Blood Pressure Medication

Furosemide

Summary

Furosemide is a loop diuretic used to treat hypertension and edema in congestive heart failure, liver cirrhosis, renal disease, and hypertension.

Brand Names

Lasix

Generic Name

Furosemide

DrugBank Accession Number

DB00695

Background

Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative.⁹ Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure.¹⁰ It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients.¹ The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.⁹

Type

Small Molecule

Groups

Approved, Vet approved

Structure

Weight: Average: 330.744
Monoisotopic: 330.007719869
Chemical Formula: C₁₂H₁₁ClN₂O₅S

Synonyms

2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid
Frusemide
Furosemid
Furosemida
Furosemide
Furosemidu
Furosemidum

External IDs

LB-502
NSC-269420

Indication

Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.⁹

Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications.¹²

Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired.⁹

Pharmacology

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

Build, train, & validate predictive machine-learning models with structured datasets.

Associated Conditions

Acute Pulmonary Edema
Ascites
Body Fluid Retention
Edema
High Blood Pressure (Hypertension)
Mild to Moderate Hypertension

Contraindications & Blackbox Warnings

Contraindications

Avoid life-threatening adverse drug events

Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Avoid life-threatening adverse drug events & improve clinical decision support.

Pharmacodynamics

Furosemide manages hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome. Furosemide is a potent loop diuretic that works to increase the excretion of Na+ and water by the kidneys by inhibiting their reabsorption from the proximal and distal tubules, as well as the loop of Henle.⁹ It works directly acts on the cells of the nephron and indirectly modifies the content of the renal filtrate.⁸ Ultimately, furosemide increases the urine output by the kidney. Protein-bound furosemide is delivered to its site of action in the kidneys and secreted via active secretion by nonspecific organic transporters expressed at the luminal site of action.^4,9

Following oral administration, the onset of the diuretic effect is about 1 and 1.5 hours ⁹, and the peak effect is reached within the first 2 hours.¹⁰ The duration of effect following oral administration is about 4-6 hours but may last up to 8 hours.¹² Following intravenous administration, the onset of effect is within 5 minutes, and the peak effect is reached within 30 minutes. The duration of action following intravenous administration is approximately 2 hours. Following intramuscular administration, the onset of action is somewhat delayed.⁹

Mechanism of action

Furosemide promotes diuresis by blocking tubular reabsorption of sodium and chloride in the proximal and distal tubules, as well as in the thick ascending loop of Henle. This diuretic effect is achieved through the competitive inhibition of sodium-potassium-chloride cotransporters (NKCC2) expressed along these tubules in the nephron, preventing the transport of sodium ions from the lumenal side into the basolateral side for reabsorption. This inhibition results in increased excretion of water along with sodium, chloride, magnesium, calcium, hydrogen, and potassium ions.¹⁰ As with other loop diuretics, furosemide decreases the excretion of uric acid.⁸

Furosemide exerts direct vasodilatory effects, which results in its therapeutic effectiveness in the treatment of acute pulmonary edema. Vasodilation leads to reduced responsiveness to vasoconstrictors, such as angiotensin II and noradrenaline, and decreased production of endogenous natriuretic hormones with vasoconstricting properties. It also leads to increased production of prostaglandins with vasodilating properties. Furosemide may also open potassium channels in resistance arteries.⁸ The main mechanism of action of furosemide is independent of its inhibitory effect on carbonic anhydrase and aldosterone.⁹

Target	Actions	Organism
ASolute carrier family 12 member 1	inhibitor	Humans
NCarbonic anhydrase 2	inhibitor	Humans
UG-protein coupled receptor 35	agonist	Humans

Absorption

Following oral administration, furosemide is absorbed from the gastrointestinal tract.¹² It displays variable bioavailability from oral dosage forms, ranging from 10 to 90%.⁴ The oral bioavailability of furosemide from oral tablets or oral solution is about 64% and 60%, respectively, of that from an intravenous injection of the drug.⁹

Volume of distribution

The volume of distribution following intravenous administration of 40 mg furosemide were 0.181 L/kg in healthy subjects and 0.140 L/kg in patients with heart failure.⁶

Protein binding

Plasma concentrations ranging from 1 to 400 mcg/mL are about 91-99% bound in healthy individuals. The unbound fraction is about 2.3-4.1% at therapeutic concentrations.¹² Furosemide mainly binds to serum albumin.⁹

Metabolism

The metabolism of furosemide occurs mainly in the kidneys and the liver, to a smaller extent. The kidneys are responsible for about 85% of total furosemide total clearance, where about 40% involves biotransformation.⁵ Two major metabolites of furosemide are furosemide glucuronide, which is pharmacologically active, and saluamine (CSA) or 4-chloro-5-sulfamoylanthranilic acid.²

Hover over products below to view reaction partners

Route of elimination

The kidneys are responsible for 85% of total furosemide total clearance, where about 43% of the drug undergoes renal excretion.⁵ Significantly more furosemide is excreted in urine following the I.V. injection than after the tablet or oral solution. Approximately 50% of the furosemide load is excreted unchanged in urine, and the rest is metabolized into glucuronide in the kidney.⁴

Half-life

The half-life from the dose of 40 mg furosemide was 4 hours following oral administration and 4.5 hours following intravenous administration. The terminal half-life of furosemide is approximately 2 hours following parenteral administration.⁹ The terminal half-life may be increased up to 24 hours in patients with severe renal failure.¹²

Clearance

Following intravenous administration of 400 mg furosemide, the plasma clearance was 1.23 mL/kg/min in patients with heart failure and 2.34 mL/kg/min in healthy subjects, respectively.⁶

Adverse Effects

Adverseeffects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Improve decision support & research outcomes with our structured adverse effects data.

Toxicity

Clinical consequences from overdose depend on the extent of electrolyte and fluid loss and include dehydration, blood volume reduction, hypotension, electrolyte imbalance, hypokalemia, hypochloremic alkalosis,⁹ hemoconcentration, cardiac arrhythmias (including A-V block and ventricular fibrillation).¹² Symptoms of overdose include acute renal failure, thrombosis, delirious states, flaccid paralysis, apathy and confusion. In cirrhotic patients, overdosage might precipitate hepatic coma.¹²

In rats, the oral LD₅₀, intraperitoneal LD₅₀, and subcutaneous LD₅₀ is 2600 mg/kg, 800 mg/kg, and 4600 mg/kg, respectively. The Lowest published toxic dose (TDLo) in a female is 6250 μg/kg.¹¹

Pathways

Pathway	Category
Furosemide Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Approved
Vet approved
Nutraceutical
Illicit
Withdrawn
Investigational
Experimental
All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Abacavir	Furosemide may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
Acamprosate	The excretion of Acamprosate can be decreased when combined with Furosemide.
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Furosemide.
Acebutolol	Furosemide may increase the hypotensive activities of Acebutolol.
Aceclofenac	The therapeutic efficacy of Furosemide can be decreased when used in combination with Aceclofenac.
Acemetacin	Furosemide may increase the nephrotoxic activities of Acemetacin.
Acetaminophen	Furosemide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.
Acetazolamide	Acetazolamide may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Furosemide.
Acetyldigitoxin	The risk or severity of adverse effects can be increased when Furosemide is combined with Acetyldigitoxin.

Food Interactions

Avoid excessive or chronic alcohol consumption. Alcohol increases the risk of orthostatic hypotension.
Avoid natural licorice. Avoid licorice in large amounts, as it may lead to hypokalemia.
Increase consumption of potassium-rich foods. This medication may cause potassium depletion. Foods containing potassium include bananas and orange juice.

Products2

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access drug product information from over 10 global regions.

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Furosemide sodium	101EM454S7	41733-55-5	DLFCAVBMDSKMEY-UHFFFAOYSA-M

Product Images

International/Other Brands

Diurapid (Mibe Jena) / Diurin (Mylan) / Diurmessel (Biomep) / Eutensin (Sanofi) / Frumex / Frusenex / Frusol (Rosemont) / Furo-Puren (Actavis) / Seguril (Sanofi)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Fuosemide	Tablet	40 mg/1	Oral	NCS HealthCare of KY, Inc dba Vangard Labs	1983-11-10	2022-10-31
Furosemide	Tablet	40 mg/1	Oral	REMEDYREPACK INC.	2017-10-27	2020-05-06
Furosemide	Injection	10 mg/1mL	Intravenous	American Regent	1990-09-30	2017-01-18
Furosemide	Injection, solution	10 mg/1mL	Intramuscular; Intravenous	HF Acquisition Co LLC, DBA HealthFirst	2018-09-14	Not applicable
Furosemide	Tablet	20 mg/1	Oral	Vintage Pharmaceuticals, LLC	2007-09-13	2007-09-13
Furosemide	Tablet	20 mg/1	Oral	bryant ranch prepack	1983-11-10	2018-02-28
Furosemide	Tablet	80 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	1981-10-19	Not applicable
Furosemide	Injection, solution	10 mg/1mL	Intramuscular; Intravenous	HF Acquisition Co LLC, DBA HealthFirst	2021-06-28	Not applicable
Furosemide	Tablet	40 mg/1	Oral	Mylan Pharmaceuticals Inc.	1981-08-27	Not applicable
Furosemide	Tablet	20 mg/1	Oral	Cardinal Health	1983-11-10	2010-04-30

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo Furosemide Tab 20mg	Tablet	20 mg	Oral	Apotex Corporation	1977-12-31	Not applicable
Apo Furosemide Tab 40mg	Tablet	40 mg	Oral	Apotex Corporation	1976-12-31	Not applicable
Apo Furosemide Tab 80mg	Tablet	80 mg	Oral	Apotex Corporation	1986-12-31	Not applicable
Ava-furosemide	Tablet	80 mg	Oral	Avanstra Inc	2011-08-11	2014-08-21
Ava-furosemide	Tablet	40 mg	Oral	Avanstra Inc	2011-08-11	2014-08-21
Ava-furosemide	Tablet	20 mg	Oral	Avanstra Inc	2011-08-11	2014-08-21
Bio-furosemide	Tablet	40 mg	Oral	Biomed Pharma	2003-04-11	Not applicable
Bio-furosemide	Tablet	20 mg	Oral	Biomed Pharma	2003-04-11	Not applicable
Dom-furosemide	Tablet	40 mg	Oral	Biomed Pharma	2003-10-14	2013-08-02
Dom-furosemide	Tablet	20 mg	Oral	Biomed Pharma	2003-10-14	2013-08-02

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Active-Medicated specimen collection kit	Furosemide (20 mg/1) + Benzalkonium chloride (0.0013 g/1mL)	Kit	Oral; Topical	N.O.R.T.H., Inc.	2013-10-31	Not applicable
Diascreen 12-Panel Medicated Collection System	Furosemide (20 mg/1) + Benzalkonium chloride (0.13 g/100g)	Kit	Oral; Topical	It3 Medical Llc	2016-07-27	Not applicable
Diuscreen Medicated Collection Kit	Furosemide (20 mg/1) + Benzalkonium chloride (0.0013 g/1mL)	Kit	Oral; Topical	Maveron Health, LLC.	2015-06-01	2016-10-28
Diuscreen Multi-Drug Medicated Test Kit	Furosemide (20 mg/1) + Benzalkonium chloride (0.0013 g/1mL)	Kit	Oral; Topical	Maveron Health, LLC.	2015-06-01	2016-10-28
Rx-Specimen Collection Kit	Furosemide (20 mg/1) + Benzalkonium chloride (0.0013 g/1mL)	Kit	Oral; Topical	Mas Management Group Inc.	2015-07-23	Not applicable
SEMİTONE 100/20 MG FILM TABLET, 10 ADET	Furosemide (20 mg) + Spironolactone (100 mg)	Tablet, film coated	Oral	World Medicine Ilac San. Ve Tic. a.s.	2020-08-14	Not applicable
SEMİTONE 100/20 MG FILM TABLET, 20 ADET	Furosemide (20 mg) + Spironolactone (100 mg)	Tablet, film coated	Oral	World Medicine Ilac San. Ve Tic. a.s.	2020-08-14	Not applicable
SEMİTONE 100/20 MG FILM TABLET, 30 ADET	Furosemide (20 mg) + Spironolactone (100 mg)	Tablet, film coated	Oral	World Medicine Ilac San. Ve Tic. a.s.	2020-08-14	Not applicable
SEMİTONE 50/20 MG FILM TABLET, 10 ADET	Furosemide (20 mg) + Spironolactone (50 mg)	Tablet, film coated	Oral	World Medicine Ilac San. Ve Tic. a.s.	2020-08-14	Not applicable
SEMİTONE 50/20 MG FILM TABLET, 20 ADET	Furosemide (20 mg) + Spironolactone (50 mg)	Tablet, film coated	Oral	World Medicine Ilac San. Ve Tic. a.s.	2020-08-14	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Furosemide	Furosemide (20 mg/1)	Tablet	Oral	Remedy Repack	2010-11-01	2011-02-10
Specimen Collection Kit	Furosemide (20 mg/1) + Benzalkonium chloride (0.13 mg/1mL)	Kit	Oral	Alvix Laboratories, LLC	2015-04-21	2019-01-28

ATC Codes

C03EB01 — Furosemide and potassium-sparing agents

C03EB — High-ceiling diuretics and potassium-sparing agents
C03E — DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION
C03 — DIURETICS
C — CARDIOVASCULAR SYSTEM

C03CA01 — Furosemide

C03CA — Sulfonamides, plain
C03C — HIGH-CEILING DIURETICS
C03 — DIURETICS
C — CARDIOVASCULAR SYSTEM

G01AE10 — Combinations of sulfonamides

G01AE — Sulfonamides
G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
G — GENITO URINARY SYSTEM AND SEX HORMONES

C03CB01 — Furosemide and potassium

C03CB — Sulfonamides and potassium in combination
C03C — HIGH-CEILING DIURETICS
C03 — DIURETICS
C — CARDIOVASCULAR SYSTEM

Drug Categories

Acids, Carbocyclic
Amides
Amines
Aminobenzoates
Aniline Compounds
Antihypertensive Agents
Antihypertensive Agents Indicated for Hypertension
Benzene Derivatives
Benzoates
Cardiovascular Agents
Diuretics
Drugs causing inadvertant photosensitivity
Drugs that are Mainly Renally Excreted
High-Ceiling Diuretics
High-Ceiling Diuretics and Potassium-Sparing Agents
Hyperglycemia-Associated Agents
Hypotensive Agents
Increased Diuresis at Loop of Henle
Membrane Transport Modulators
Natriuretic Agents
Nephrotoxic agents
Non Potassium Sparing Diuretics
OAT1/SLC22A6 inhibitors
OAT3/SLC22A8 Inhibitors
Ototoxic agents
Photosensitizing Agents
Sodium Potassium Chloride Symporter Inhibitors
Sulfanilamides
Sulfonamides
Sulfones
Sulfur Compounds
Thyroxine-binding globulin substrates
UGT1A1 Substrates

Chemical TaxonomyProvided by Classyfire

Description: This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
Kingdom: Organic compounds
Super Class: Benzenoids
Class: Benzene and substituted derivatives
Sub Class: Benzenesulfonamides
Direct Parent: Aminobenzenesulfonamides
Alternative Parents: 4-halobenzoic acids / Aminobenzoic acids / Halobenzoic acids / Benzenesulfonyl compounds / Benzoic acids / Aniline and substituted anilines / Benzoyl derivatives / Phenylalkylamines / Secondary alkylarylamines / Chlorobenzenes / Organosulfonamides / Aryl chlorides / Furans / Vinylogous amides / Aminosulfonyl compounds / Heteroaromatic compounds / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Oxacyclic compounds / Organic oxides / Organochlorides / Organooxygen compounds / Organopnictogen compounds / Hydrocarbon derivatives show 15 more
Substituents: 4-halobenzoic acid / 4-halobenzoic acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Aminobenzenesulfonamide / Aminobenzoic acid / Aminobenzoic acid or derivatives / Aminosulfonyl compound / Aniline or substituted anilines / Aralkylamine / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Benzenesulfonyl group / Benzoic acid / Benzoic acid or derivatives / Benzoyl / Carboxylic acid / Carboxylic acid derivative / Chlorobenzene / Furan / Halobenzene / Halobenzoic acid / Halobenzoic acid or derivatives / Heteroaromatic compound / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organic sulfonic acid or derivatives / Organochloride / Organohalogen compound / Organoheterocyclic compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Organosulfonic acid amide / Organosulfonic acid or derivatives / Organosulfur compound / Oxacycle / Phenylalkylamine / Secondary aliphatic/aromatic amine / Secondary amine / Sulfonyl / Vinylogous amide show 37 more
Molecular Framework: Aromatic heteromonocyclic compounds
External Descriptors: sulfonamide, furans, chlorobenzoic acid (CHEBI:47426)

Affected organisms

Humans and other mammals

UNII: 7LXU5N7ZO5
CAS number: 54-31-9
InChI Key: ZZUFCTLCJUWOSV-UHFFFAOYSA-N
InChI: InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)
IUPAC Name: 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
SMILES: NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O

Synthesis Reference

Angelo Signor, Alfredo Guerrato, Giovanni Signor, "Process for the preparation of furosemide." U.S. Patent US5739361, issued June, 1971.

US5739361

General References

Prandota J: Clinical pharmacology of furosemide in children: a supplement. Am J Ther. 2001 Jul-Aug;8(4):275-89. [Article]
Ponto LL, Schoenwald RD: Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). Clin Pharmacokinet. 1990 May;18(5):381-408. doi: 10.2165/00003088-199018050-00004. [Article]
Prandota J: Furosemide: progress in understanding its diuretic, anti-inflammatory, and bronchodilating mechanism of action, and use in the treatment of respiratory tract diseases. Am J Ther. 2002 Jul-Aug;9(4):317-28. [Article]
Oh SW, Han SY: Loop Diuretics in Clinical Practice. Electrolyte Blood Press. 2015 Jun;13(1):17-21. doi: 10.5049/EBP.2015.13.1.17. Epub 2015 Jun 30. [Article]
Pichette V, du Souich P: Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. J Am Soc Nephrol. 1996 Feb;7(2):345-9. [Article]
Andreasen F, Mikkelsen E: Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure. Eur J Clin Pharmacol. 1977 Aug 17;12(1):15-22. doi: 10.1007/bf00561400. [Article]
Perez J, Sitar DS, Ogilvie RI: Biotransformation of furosemide in patients with acute pulmonary edema. Drug Metab Dispos. 1979 Nov-Dec;7(6):383-7. [Article]
28. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 352-354). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
Furosemide - FDA Label [Link]
Furosemide - StatPearls - NCBI Bookshelf [Link]
Furosemide SAFETY DATA SHEET - Cayman Chemical [Link]
Lasix Oral (furosemide) Product Monograph [Link]

External Links

Human Metabolome Database: HMDB0001933
KEGG Drug: D00331
KEGG Compound: C07017
PubChem Compound: 3440
PubChem Substance: 46506779
ChemSpider: 3322
BindingDB: 25902
RxNav: 4603
ChEBI: 47426
ChEMBL: CHEMBL35
ZINC: ZINC000000035804
Therapeutic Targets Database: DAP000043
PharmGKB: PA449719
PDBe Ligand: FUN
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
Wikipedia: Furosemide

PDB Entries

1z9y / 2xn5 / 3rf4 / 6de9 / 6sg0

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Other	Cystoscopy	1
4	Completed	Prevention	Congestive Heart Failure (CHF) / Edema / High Blood Pressure (Hypertension) / Hypotension	1
4	Completed	Prevention	Diabetic Nephropathy	1
4	Completed	Prevention	High Blood Pressure (Hypertension)	1
4	Completed	Treatment	Acute Decompensated Heart Failure (ADHF)	1
4	Completed	Treatment	Acute Heart Failure (AHF)	1
4	Completed	Treatment	Ascites / Cirrhosis of the Liver	2
4	Completed	Treatment	Chronic Heart Failure (CHF) / Congestive Heart Failure (CHF)	1
4	Completed	Treatment	Chronic Kidney Disease (CKD)	1
4	Completed	Treatment	Colorectal Disorders	1

Manufacturers

Abraxis pharmaceutical products
App pharmaceuticals llc
Astrazeneca lp
Baxter healthcare corp anesthesia and critical care
Hospira inc
International medication system
Luitpold pharmaceuticals inc
Marsam pharmaceuticals llc
Organon usa inc
Smith and nephew solopak div smith and nephew
Warner chilcott div warner lambert co
Watson laboratories inc
Wockhardt ltd
Wyeth ayerst laboratories
Sanofi aventis us llc
Roxane laboratories inc
Wockhardt eu operations (swiss) ag
Dava pharmaceuticals inc
Excellium pharmaceutical inc
International medication systems ltd
Ipca laboratories ltd
Ivax pharmaceuticals inc sub teva pharmaceuticals usa
Kalapharm inc
Mutual pharmaceutical co inc
Mylan pharmaceuticals inc
Sandoz inc
Superpharm corp
Vintage pharmaceuticals inc
County line pharmaceuticals llc

Packagers

Advanced Pharmaceutical Services Inc.
American Regent
Amerisource Health Services Corp.
Apotheca Inc.
APP Pharmaceuticals
A-S Medication Solutions LLC
Bryant Ranch Prepack
C.O. Truxton Inc.
Cardinal Health
Central Texas Community Health Centers
Comprehensive Consultant Services Inc.
Coupler Enterprises Inc.
CVS Pharmacy
DAVA Pharmaceuticals
Dept Health Central Pharmacy
DHHS Program Support Center Supply Service Center
Direct Dispensing Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Excellium Pharmaceutical Inc.
General Injectables and Vaccines Inc.
Goldline Laboratories Inc.
Group Health Cooperative
H and H Laboratories
Heartland Repack Services LLC
Hospira Inc.
Intervet International
Ipca Laboratories Ltd.
Ivax Pharmaceuticals
Kaiser Foundation Hospital
Lake Erie Medical and Surgical Supply
Liberty Pharmaceuticals
Luitpold Pharmaceuticals Inc.
Macnary Ltd.
Major Pharmaceuticals
Mason Distributors
Mckesson Corp.
Medvantx Inc.
Merrell Pharmaceuticals Inc.
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Neighborcare Repackaging Inc.
Neuman Distributors Inc.
Norwich Pharmaceuticals Inc.
Nucare Pharmaceuticals Inc.
Ohm Laboratories Inc.
Palmetto Pharmaceuticals Inc.
Patheon Inc.
PCA LLC
PD-Rx Pharmaceuticals Inc.
Pharmaceutical Utilization Management Program VA Inc.
Pharmedix
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepackage Specialists
Prepak Systems Inc.
Qualitest
Ranbaxy Laboratories
Rebel Distributors Corp.
Redpharm Drug
Remedy Repack
Roxane Labs
Sandhills Packaging Inc.
Sandoz
Sanofi-Aventis Inc.
Southwood Pharmaceuticals
Spectrum Pharmaceuticals
Stat Scripts LLC
Talbert Medical Management Corp.
Taylor Pharmaceuticals
Tya Pharmaceuticals
UDL Laboratories
United Research Laboratories Inc.
Va Cmop Dallas
Vangard Labs Inc.
Vatring Pharmaceuticals
Vedco Inc.
Vintage Pharmaceuticals Inc.
Watson Pharmaceuticals
Wockhardt Ltd.

Dosage Forms

Form	Route	Strength
Kit	Oral; Topical
Tablet	Oral	20 mg
Tablet	Oral	40 mg
Solution		10 mg/1ml
Tablet	Oral
Tablet	Oral
Tablet	Oral	40.00 mg
Tablet	Oral	250 MG
Injection, solution, concentrate	Parenteral	250 mg
Injection, solution	Intravenous	40 mg/4ml
Capsule, extended release	Oral	120 MG
Tablet	Oral	125 MG
Capsule, extended release	Oral	30 MG
Injection, solution	Parenteral	40 MG/4ML
Capsule, extended release	Oral	60 MG
Solution	Parenteral	10 MG/ML
Solution	Parenteral	250 MG/25ML
Solution	Intravenous	20 mg
Solution	Parenteral	20 mg
Tablet, film coated	Oral	40 mg
Capsule, coated	Oral
Injection	Intramuscular; Intravascular	10 mg/1mL
Injection	Intramuscular; Intravenous	10 mg/2mL
Injection	Intramuscular; Intravenous	10 mg/1mL
Injection	Intramuscular; Intravenous	100 mg/10mL
Injection	Intramuscular; Intravenous	20 mg/2mL
Injection	Intramuscular; Intravenous	40 mg/4mL
Injection	Intravenous	10 mg/1mL
Injection, solution	Intramuscular; Intravenous
Injection, solution	Intramuscular; Intravenous	10 mg/1mL
Injection, solution	Intramuscular; Intravenous	100 mg/10mL
Injection, solution	Intramuscular; Intravenous	20 mg/2mL
Injection, solution	Intramuscular; Intravenous	40 mg/4mL
Injection, solution	Intravenous	10 mg/1mL
Solution	Oral	10 mg/1mL
Solution	Oral	40 mg/4mL
Solution	Oral	40 mg/5mL
Tablet	Oral	20 mg/1
Tablet	Oral	40 mg/1
Tablet	Oral	80 mg/1
Tablet, film coated	Oral
Injection, solution	Parenteral	10 MG/ML
Injection, solution		10 MG/ML
Injection, solution	Intravenous	20 mg/2ml
Injection, solution
Liquid	Intramuscular; Intravenous	10 mg / mL
Solution	Intramuscular; Intravenous	10 mg / mL
Solution	Intramuscular; Intravenous	20 mg / 2 mL
Injection, solution		20 MG/2ML
Tablet	Oral	25 MG
Solution	Intravenous	250 mg / 25 mL
Liquid	Intravenous	250 mg / 25 mL
Solution	Intravenous	10 mg / mL
Tablet	Oral	80 mg
Injection, solution	Intramuscular; Intravenous	50 mg/5mL
Injection	Intramuscular; Intravenous	10 mg/ml
Injection	Intramuscular; Intravenous
Drug delivery system	Topical	20 mg
Capsule, gelatin coated	Oral
Capsule	Oral
Injection, solution		250 MG/25ML
Solution	Oral	10 MG/ML
Injection, solution, concentrate	Intravenous	250 mg/25mL
Solution	Parenteral	250 MG
Tablet	Oral	80 mg / tab
Injection, solution	Parenteral	20 MG/2ML
Liquid	Oral	10 mg / mL
Solution	Oral	10 mg / mL
Liquid	Intramuscular; Intravenous	20 mg / 2 mL
Capsule	Oral	30 mg
Capsule	Oral	60 mg
Liquid	Intravenous	10 mg / mL
Tablet, film coated	Oral
Kit	Oral
Injection, solution	Parenteral
Injection
Solution	Intramuscular; Intravenous
Kit	Not applicable; Oral; Topical
Solution	Intramuscular; Intravenous	20 mg
Solution	Oral
Tablet, coated	Oral	40 mg
Tablet	Oral	500 mg
Injection, solution		10 mg/1ml

Prices

Unit description	Cost	Unit
Hydro 40 40% Foam 150 gm Can	182.52USD	can
Hydro 40 40% Foam 70 gm Can	148.99USD	can
Furosemide 10 mg/ml Solution 60ml Bottle	17.99USD	bottle
Furosemide 10 mg/ml Solution 120ml Bottle	15.98USD	bottle
Furosemide powder	3.51USD	g
Lasix Special 500 mg Tablet	3.25USD	tablet
Urex 1 gm tablet	2.47USD	tablet
Furosemide 10 mg/ml cartrg	1.45USD	ml
Lasix 80 mg tablet	1.0USD	tablet
Furosemide 10 mg/ml Solution	0.9USD	ml
Furosemide 10 mg/ml	0.75USD	ml
Lasix 40 mg tablet	0.53USD	tablet
Furosemide 80 mg tablet	0.45USD	tablet
Lasix 20 mg tablet	0.42USD	tablet
Lasix 10 mg/ml Solution	0.3USD	ml
CVS Pharmacy diuretic 50 mg softgel	0.17USD	softgel capsule
Furosemide 40 mg tablet	0.16USD	tablet
Furosemide 20 mg tablet	0.14USD	tablet
Apo-Furosemide 80 mg Tablet	0.13USD	tablet
Novo-Semide 80 mg Tablet	0.13USD	tablet
Nat herbal diuretic tablet sa	0.1USD	tablet
Apo-Furosemide 40 mg Tablet	0.07USD	tablet
Natural herbal diuretic tablet	0.07USD	tablet
Novo-Semide 40 mg Tablet	0.07USD	tablet
Apo-Furosemide 20 mg Tablet	0.05USD	tablet
Novo-Semide 20 mg Tablet	0.05USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	220	MSDS
water solubility	73.1 mg/L (at 30 °C)	YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP	2.03	SANGSTER (1993)
logS	-3.66	ADME Research, USCD
Caco2 permeability	-6.5	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	0.118 mg/mL	ALOGPS
logP	2.71	ALOGPS
logP	1.75	ChemAxon
logS	-3.4	ALOGPS
pKa (Strongest Acidic)	4.25	ChemAxon
pKa (Strongest Basic)	-1.5	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	122.63 Å²	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	77.47 m³·mol^-1	ChemAxon
Polarizability	30.55 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9155
Blood Brain Barrier	-	0.8833
Caco-2 permeable	-	0.6436
P-glycoprotein substrate	Non-substrate	0.8775
P-glycoprotein inhibitor I	Non-inhibitor	0.9272
P-glycoprotein inhibitor II	Non-inhibitor	0.8382
Renal organic cation transporter	Non-inhibitor	0.924
CYP450 2C9 substrate	Non-substrate	0.6878
CYP450 2D6 substrate	Non-substrate	0.8351
CYP450 3A4 substrate	Non-substrate	0.6789
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.907
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Non-inhibitor	0.9602
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.6885
Ames test	Non AMES toxic	0.9132
Carcinogenicity	Non-carcinogens	0.6469
Biodegradation	Not ready biodegradable	0.9881
Rat acute toxicity	2.1362 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9342
hERG inhibition (predictor II)	Non-inhibitor	0.8525

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
MS/MS Spectrum - Quattro_QQQ 10V, N/A	LC-MS/MS	splash10-03dr-0090000000-da505a3f09285d049f34
MS/MS Spectrum - Quattro_QQQ 25V, N/A	LC-MS/MS	splash10-0f89-2190000000-53c91100e89c81f0fa30
MS/MS Spectrum - Quattro_QQQ 40V, N/A	LC-MS/MS	splash10-01ox-9660000000-83d8486cbca0dd3487c9
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-000i-0090000000-f3a3dcb92cfcdff9f7dc
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-004i-0019000000-946089b12d2ab6fd05a4
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-000i-0090000000-04af1dec204d462d4bc4
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-0udi-1090000000-1af70d23e1a0ebaa0878
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-004i-9770000000-0c5cd578b5b69a1a61d4
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-004i-9800000000-3303b20f9b23e24ae312
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-004i-9400000000-23cfec716ac8fbcb092f
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-004i-0019000000-e73aa1d969ab4255732b
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-000i-0090000000-33053544119c01ac6b45
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-0udi-1090000000-7029ab63efa73a3ff88d
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-004i-9670000000-4bad8928bbcfc85f431f
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-004i-9800000000-2193e38e314f2b18be26
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-004i-9600000000-e703f7ab6221182df156
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-000i-0090000000-f3645e993869ff3886ba
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-000i-0090000000-18400153a811f7100a2f
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-0f79-0090000000-7e491b92dab050fb81c0
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-000i-0090000000-8e41d38fe799d96230a6
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-000i-0090000000-cfec4a54171c58245919
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-0ug0-0193000000-b55039ca13cbc3acd9a8
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0udi-0290000000-1f1017fe4370d9541f6d
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-001i-9110000000-505f1e781d384073f688
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-001j-9000000000-cd886e0521fb4d1bdc82
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-000t-9000000000-8a69e99643ee37bc1883
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-000t-9000000000-f7ac3c9eea39ed725cfc
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-000t-9000000000-8a294fd51a34073aa4a1
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0002-9000000000-b16e204dec9ae7938d40
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0f8a-9220000000-3bde836fe7e67c9b8755
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-000t-9000000000-9025c2261c96ca3aa551
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-000t-9000000000-8d05f828403d0fe7cac4
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0002-9000000000-3cd4f8015eb5fafacacb
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0002-9000000000-34937031271e62c39c1f
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0002-9000000000-40e9966d335f71aedb96
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0udi-0290000000-586707fb0116e8b61643
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-001i-9000000000-f6727b05eb8ee02a6e7c
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-00di-0090000000-51662bec1d461d0f0a5a
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-00di-0090000000-8eea44e0dd27bb59939d
1H NMR Spectrum	1D NMR	Not Applicable
[1H,13C] 2D NMR Spectrum	2D NMR	Not Applicable

Targets

Drugtargets2

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Inhibitor

General Function: Sodium:potassium:chloride symporter activity
Specific Function: Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name: SLC12A1
Uniprot ID: Q13621
Uniprot Name: Solute carrier family 12 member 1
Molecular Weight: 121449.13 Da

References

Brater DC: Pharmacology of diuretics. Am J Med Sci. 2000 Jan;319(1):38-50. [Article]
Davies DL, Wilson GM: Diuretics: mechanism of action and clinical application. Drugs. 1975;9(3):178-226. [Article]
Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, Nurnberg P, Brockmoller J: Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25. [Article]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Gimenez I: Molecular mechanisms and regulation of furosemide-sensitive Na-K-Cl cotransporters. Curr Opin Nephrol Hypertens. 2006 Sep;15(5):517-23. doi: 10.1097/01.mnh.0000242178.44576.b0. [Article]
Limmer F, Schinner E, Castrop H, Vitzthum H, Hofmann F, Schlossmann J: Regulation of the Na(+)-K(+)-2Cl(-) cotransporter by cGMP/cGMP-dependent protein kinase I after furosemide administration. FEBS J. 2015 Oct;282(19):3786-98. doi: 10.1111/febs.13376. Epub 2015 Jul 30. [Article]

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Inhibitor

General Function: Zinc ion binding
Specific Function: Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name: CA2
Uniprot ID: P00918
Uniprot Name: Carbonic anhydrase 2
Molecular Weight: 29245.895 Da

References

Ranjbar S, Ghobadi S, Khodarahmi R, Nemati H: Spectroscopic characterization of furosemide binding to human carbonic anhydrase II. Int J Biol Macromol. 2012 May 1;50(4):910-7. doi: 10.1016/j.ijbiomac.2012.02.005. Epub 2012 Feb 16. [Article]
Supuran CT: Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des. 2008;14(7):641-8. [Article]

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Agonist

General Function: G-protein coupled receptor activity
Specific Function: Acts as a receptor for kynurenic acid, an intermediate in the tryptophan metabolic pathway. The activity of this receptor is mediated by G-proteins that elicit calcium mobilization and inositol pho...
Gene Name: GPR35
Uniprot ID: Q9HC97
Uniprot Name: G-protein coupled receptor 35
Molecular Weight: 34071.89 Da

References

Yang Y, Fu A, Wu X, Reagan JD: GPR35 is a target of the loop diuretic drugs bumetanide and furosemide. Pharmacology. 2012;89(1-2):13-7. doi: 10.1159/000335127. Epub 2012 Jan 10. [Article]
Divorty N, Milligan G, Graham D, Nicklin SA: The Orphan Receptor GPR35 Contributes to Angiotensin II-Induced Hypertension and Cardiac Dysfunction in Mice. Am J Hypertens. 2018 Aug 3;31(9):1049-1058. doi: 10.1093/ajh/hpy073. [Article]
Divorty N, Mackenzie AE, Nicklin SA, Milligan G: G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease. Front Pharmacol. 2015 Mar 10;6:41. doi: 10.3389/fphar.2015.00041. eCollection 2015. [Article]

Enzymes

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Phosphogluconate dehydrogenase (decarboxylating) activity
Specific Function: Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
Gene Name: PGD
Uniprot ID: P52209
Uniprot Name: 6-phosphogluconate dehydrogenase, decarboxylating
Molecular Weight: 53139.56 Da

References

Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Aug;25(4):476-9. doi: 10.3109/14756360903257900. [Article]
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Steroid binding
Specific Function: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name: UGT1A1
Uniprot ID: P22309
Uniprot Name: UDP-glucuronosyltransferase 1-1
Molecular Weight: 59590.91 Da

References

Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10. [Article]

Carriers

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Binder

General Function: Toxic substance binding
Specific Function: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name: ALB
Uniprot ID: P02768
Uniprot Name: Serum albumin
Molecular Weight: 69365.94 Da

References

Lebedev AA, Samokrutova OV: [Study of the binding of diuretics by serum proteins according to changes in tryptophan fluorescence]. Farmakol Toksikol. 1989 May-Jun;52(3):40-3. [Article]
Furosemide - FDA Label [Link]

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Binder

General Function: Serine-type endopeptidase inhibitor activity
Specific Function: Major thyroid hormone transport protein in serum.
Gene Name: SERPINA7
Uniprot ID: P05543
Uniprot Name: Thyroxine-binding globulin
Molecular Weight: 46324.12 Da

References

Stockigt JR, Lim CF, Barlow JW, Wynne KN, Mohr VS, Topliss DJ, Hamblin PS, Sabto J: Interaction of furosemide with serum thyroxine-binding sites: in vivo and in vitro studies and comparison with other inhibitors. J Clin Endocrinol Metab. 1985 May;60(5):1025-31. doi: 10.1210/jcem-60-5-1025. [Article]
CYTOMEL (liothyronine) FDA label [File]

Transporters

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Inhibitor

Inducer

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name: SLC22A6
Uniprot ID: Q4U2R8
Uniprot Name: Solute carrier family 22 member 6
Molecular Weight: 61815.78 Da

References

Kim GH, Na KY, Kim SY, Joo KW, Oh YK, Chae SW, Endou H, Han JS: Up-regulation of organic anion transporter 1 protein is induced by chronic furosemide or hydrochlorothiazide infusion in rat kidney. Nephrol Dial Transplant. 2003 Aug;18(8):1505-11. [Article]
Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol. 1999 Jan;276(1 Pt 2):F122-8. [Article]
Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [Article]
Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [Article]

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Symporter activity
Specific Function: Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name: SLC22A5
Uniprot ID: O76082
Uniprot Name: Solute carrier family 22 member 5
Molecular Weight: 62751.08 Da

References

Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [Article]

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name: SLC22A8
Uniprot ID: Q8TCC7
Uniprot Name: Solute carrier family 22 member 8
Molecular Weight: 59855.585 Da

References

Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [Article]
Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [Article]

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Organic anion transmembrane transporter activity
Specific Function: Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name: ABCC2
Uniprot ID: Q92887
Uniprot Name: Canalicular multispecific organic anion transporter 1
Molecular Weight: 174205.64 Da

References

Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8. [Article]

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, a...
Gene Name: SLCO2A1
Uniprot ID: Q92959
Uniprot Name: Solute carrier organic anion transporter family member 2A1
Molecular Weight: 70043.33 Da

References

Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL: Identification and characterization of a prostaglandin transporter. Science. 1995 May 12;268(5212):866-9. [Article]

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name: SLC22A11
Uniprot ID: Q9NSA0
Uniprot Name: Solute carrier family 22 member 11
Molecular Weight: 59970.945 Da

References

Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [Article]

Drug created at June 13, 2005 13:24 / Updated at December 21, 2021 15:24

Source: https://go.drugbank.com/drugs/DB00695

Posted by: agnerfeliciaayes.blogspot.com

Felicia Agner

20 Mg Furosemide And 3 Blood Pressure Medication

Furosemide

Targets

References

References

References

Enzymes

References

References

Carriers

References

References

Transporters

References

References

References

References

References

References

Posting Komentar untuk "20 Mg Furosemide And 3 Blood Pressure Medication"

Menu Halaman Statis